Minimization of immunosuppression. Transplant immunology

Transplant Immunology

Volumn 20, Issue 1-2, 2008, Pages 48-54

  Patel, Jignesh ^a   Kobashigawa, Jon A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcineurin inhibitors; Corticosteroids; Heart transplantation; Immunosuppression; Proliferation signal inhibitors; Rejection

Indexed keywords

ALLOANTIBODY; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYLEX; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANTIBODY DETECTION; ARTICLE; BONE MARROW SUPPRESSION; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HIGH RISK PATIENT; HIRSUTISM; HISTOCOMPATIBILITY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DYSFUNCTION; LEUKOPENIA; MONOTHERAPY; MORBIDITY; NEPHROTOXICITY; NEUROPATHY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; SIDE EFFECT; WEIGHT GAIN;

ANTIBODIES, MONOCLONAL; CALCINEURIN; CYCLOSPORINE; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; SIROLIMUS; TACROLIMUS;

EID: 56049101353     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2008.10.001     Document Type: Article

References (56)

1. Caves P.K., Stinson E.B., Griepp R.B., Rider A.K., Dong Jr. E., and Shumway N.E. Results of 54 cardiac transplants. Surgery 74 2 (Aug 1973) 307-314
2. Taylor D.O., Edwards L.B., Boucek M.M., Trulock E.P., Aurora P., Christie J., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant 26 8 (Aug 2007) 769-781
3. Carrier M., White M., Pellerin M., Pelletier G.B., and Pelletier L.C. Comparison of Neoral and Sandimmune cyclosporine for induction of immunosuppression after heart transplantation. Can J Cardiol 13 5 (May 1997) 469-473
4. Maccherini M., Bernazzali S., Diciolla F., Giunti G., Bizzarri F., Lisi G.F., et al. Neoral versus Sandimmun: clinical impact and modification of immunosuppressive therapy in cardiac transplantation. Transplant Proc 30 5 (Aug 1998) 1904-1905
5. Yonan N.A., Aziz T., el-Gamel A., Campbell C.S., Rahman A.N., and Deiraniya A.K. Long-term safety and efficacy of Neoral in heart transplantation. Transplant Proc 30 5 (Aug 1998) 1906-1909
6. Mentzer Jr. R.M., Jahania M.S., and Lasley R.D. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. Transplantation 65 1 (Jan 15 1998) 109-113
7. Meiser B.M., Uberfuhr P., Fuchs A., Schulze C., Nollert G., Mair H., et al. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant 16 8 (Aug 1997) 795-800
8. Patel J.K., and Kobashigawa J.A. Tacrolimus in heart transplant recipients: an overview. BioDrugs 21 3 (2007) 139-143
9. Kobashigawa J., Miller L., Renlund D., Mentzer R., Alderman E., Bourge R., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 66 4 (Aug 27 1998) 507-515
10. Roussel J.C., Baron O., Perigaud C., Bizouarn P., Pattier S., Habash O., et al. Outcome of heart transplants 15 to 20 years ago: graft survival, post-transplant morbidity, and risk factors for mortality. J Heart Lung Transplant 27 5 (May 2008) 486-493
11. Kaczmarek I., Sadoni S., Schmoeckel M., Lamm P., Daebritz S., Veberfuhr P., et al. The need for a tailored immunosuppression in older heart transplant recipients. J Heart Lung Transplant 24 11 (Nov 2005) 1965-1968
12. Kobashigawa J.A., Kirklin J.K., Naftel D.C., Bourge R.C., Ventura H.O., Mohanty P.K., et al. Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. J Heart Lung Transplant 12 3 (May-Jun 1993) 355-366
13. Higgins R., Kirklin J.K., Brown R.N., Rayburn B.K., Wagoner L., Oren R., et al. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?. J Heart Lung Transplant 24 4 (Apr 2005) 392-400
14. Beniaminovitz A., Itescu S., Lietz K., Donovan M., Burke E.M., Groff B.D., et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342 9 (Mar 2 2000) 613-619
15. Kfoury A.G., Hammond M.E., Snow G.L., Stehlik J., Reid B.B., Long J.W., et al. Early screening for antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 26 12 (Dec 2007) 1264-1269
16. Kubo S.H., Naftel D.C., Mills Jr. R.M., O'Donnell J., Rodeheffer R.J., Cintron G.B., et al. Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group. J Heart Lung Transplant 14 3 (May-Jun 1995) 409-418
17. Keogh A., Macdonald P., Harvison A., Richens D., Mundy J., and Spratt P. Initial steroid-free versus steroid-based maintenance therapy and steroid withdrawal after heart transplantation: two views of the steroid question. J Heart Lung Transplant 11 2 Pt 2 (Mar-Apr 1992) 421-427
18. Yamani M.H., Taylor D.O., Czerr J., Haire C., Kring R., Zhou L., et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transplant 22 1 (Jan-Feb 2008) 76-81
19. Yacoub M., Alivizatos P., Khaghani A., and Mitchell A. The use of cyclosporine, azathioprine and anti-thymocyte globulin with or without low dose steroids for immunosuppression of cardiac transplant patients. Transplant Proc 17 (1985) 221-222
20. Esmore D.S., Spratt P.M., Keogh A.M., and Chang V.P. Cyclosporine and azathioprine immunosuppression without maintenance steroids: a prospective randomized trial. J Heart Transplant 8 3 (May-Jun 1989) 194-199
21. Lee K.F., Pierce J.D., Hess M.L., Hastillo A.K., Wechsler A.S., and Guerraty A.J. Cardiac transplantation with corticosteroid-free immunosuppression: long-term results. Ann Thorac Surg 52 2 (Aug 1991) 211-217 discussion 8
22. Renlund D.G., O'Connell J.B., Gilbert E.M., Watson F.S., and Bristow M.R. Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. J Heart Transplant 6 2 (Mar-Apr 1987) 71-78
23. Kobashigawa J.A., Stevenson L.W., Brownfield E.D., Moriguchi J.D., Kawata N., Fandrich R., et al. Initial success of steroid weaning late after heart transplantation. J Heart Lung Transplant 11 2 Pt 2 (Mar-Apr 1992) 428-430
24. Miller L.W., Wolford T., McBride L.R., Peigh P., and Pennington D.G. Successful withdrawal of corticosteroids in heart transplantation. J Heart Lung Transplant 11 2 Pt 2 (Mar-Apr 1992) 431-434
25. Ojo A.O., Held P.J., Port F.K., Wolfe R.A., Leichtman A.B., Young E.W., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 10 (Sep 4 2003) 931-940
26. Aleksic I., Baryalei M., Busch T., Pieske B., Schorn B., Strauch J., et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 69 8 (Apr 27 2000) 1586-1590
27. Angermann C.E., Stork S., Costard-Jackle A., Dengler T.J., Siebert U., Tenderich G., et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients-the IMPROVED multi-centre study. Eur Heart J 25 18 (Sep 2004) 1626-1634
28. Arizon del Prado J.M., Aumente M.D., Lopez Granados A., Siles J.R., Paulovic D., Romo E., et al. Use of mycophenolate mofetil in patients with transplanted heart and renal insufficiency: the relevance of the pharmacokinetic study. Transplant Proc 34 1 (Feb 2002) 144-145
29. Baryalei M., Zenker D., Pieske B., Tondo K., Dalichau H., and Aleksic I. Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 35 4 (Jun 2003) 1539-1542
30. Groetzner J., Kaczmarek I., Landwehr P., Mueller M., Daebritz S., Lamm P., et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardio-thorac Surg 25 3 (Mar 2004) 333-341
31. Groetzner J., Meiser B., Landwehr P., Buehse L., Mueller M., Kaczmarek I., et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 77 4 (Feb 27 2004) 568-574
32. Hunt J., Lerman M., Magee M.J., Dewey T.M., Herbert M., and Mack M.J. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant 24 11 (Nov 2005) 1863-1867
33. Meiser B., Reichart B., Adamidis I., Uberfuhr P., and Kaczmarek I. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 5 4 Pt 1 (Apr 2005) 827-831
34. Rice J.E., Shipp A.T., Carlin J.B., Vidmar S.I., and Weintraub R.G. Late reduction in cyclosporine dosage does not improve renal function in pediatric heart transplant recipients. J Heart Lung Transplant 21 10 (Oct 2002) 1109-1112
35. Tedoriya T., Keogh A.M., Kusano K., Savdie E., Hayward C., Spratt P.M., et al. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J Heart Lung Transplant 21 9 (Sep 2002) 976-982
36. Trosch F., Rothenburger M., Schneider M., Welp H., Etz C., Wilhelm M.J., et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 52 3 (Jun 2004) 163-168
37. Zakliczynski M., Nozynski J., Zakliczynska H., Rozentryt P., and Zembala M. Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation. Transplant Proc 35 6 (Sep 2003) 2331-2332
38. Hamour I.M., Lyster H.S., Burke M.M., Rose M.L., and Banner N.R. Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients. Transplantation 83 5 (Mar 15 2007) 570-576
39. Gustafsson F., Ross H.J., Delgado M.S., Bernabeo G., and Delgado D.H. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. J Heart Lung Transplant 26 10 (Oct 2007) 998-1003
40. Ross H., Pflugfelder P., Haddad H., Cantarovich M., White M., Ignaszewski A., et al. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. J Heart Lung Transplant 27 2 (Feb 2008) 197-202
41. Cantarovich M., Elstein E., de Varennes B., and Barkun J.S. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 68 12 (Dec 27 1999) 1839-1842
42. Mathias H.C., Ozalp F., Will M.B., Borland W., Payne C., Kerr M., et al. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients. J Heart Lung Transplant 24 12 (Dec 2005) 2137-2143
43. Cantarovich M., Ross H., Arizon J.M., Gomez M.A., Straatman L., Orus J., et al. Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction. Transplantation 85 7 (Apr 15 2008) 992-999
44. Kushwaha S.S., Khalpey Z., Frantz R.P., Rodeheffer R.J., Clavell A.L., Daly R.C., et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 24 12 (Dec 2005) 2129-2136
45. Raichlin E., Bae J.H., Khalpey Z., Edwards B.S., Kremers W.K., Clavell A.L., et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 116 23 (Dec 4 2007) 2726-2733
46. Hunt J., Bedanova H., Starling R., Rabago G., Banner N., Kobashigawa J., et al. Premature termination of a prospective, open label, randomized, multicenter study of sirolimus to replace calcineurin inhibitors (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation. J Heart Lung Transplant 26 suppl 2 (2007) 398
47. Baran D.A., Segura L., Kushwaha S., Courtney M., Correa R., Fallon J.T., et al. Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results. J Heart Lung Transplant 20 1 (Jan 2001) 59-70
48. Lubitz S.A., Baran D.A., Alwarshetty M.M., Pinney S., Kaplan S., Chan M., et al. Long-term results of tacrolimus monotherapy in cardiac transplant recipients. J Heart Lung Transplant 25 6 (Jun 2006) 699-706
49. Baran D.A., Zucker M.J., Arroyo L.H., Alwarshetty M.M., Ramirez M.R., Prendergast T.W., et al. Randomized trial of tacrolimus monotherapy: tacrolimus in combination, tacrolimus alone compared (the TICTAC trial). J Heart Lung Transplant 26 10 (Oct 2007) 992-997
50. Kobashigawa J.A., Stevenson L.W., Brownfield E.D., Gleeson M.P., Moriguchi J.D., Kawata N., et al. Corticosteroid weaning late after heart transplantation: relation to HLA-DR mismatching and long-term metabolic benefits. J Heart Lung Transplant 14 5 (Sep-Oct 1995) 963-967
51. Deng M.C., Eisen H.J., Mehra M.R., Billingham M., Marboe C.C., Berry G., et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 6 1 (Jan 2006) 150-160
52. Kowalski R.J., Post D.R., Mannon R.B., Sebastian A., Wright H.I., Sigle G., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82 5 (Sep 15 2006) 663-668
53. Gautam A., Morrissey P.E., Brem A.S., Fischer S.A., Gohh R.Y., Yango A.F., et al. Use of an immune function assay to monitor immunosuppression for treatment of post-transplant lymphoproliferative disorder. Pediatr Transplant 10 5 (Aug 2006) 613-616
54. Nwakanma L.U., Williams J.A., Weiss E.S., Russell S.D., Baumgartner W.A., and Conte J.V. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg 84 5 (Nov 2007) 1556-1562 discussion 62-3
55. Tambur A.R., Bray R.A., Takemoto S.K., Mancini M., Costanzo M.R., Kobashigawa J.A., et al. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation 70 7 (Oct 15 2000) 1055-1059
56. Tambur A.R., Pamboukian S.V., Costanzo M.R., Herrera N.D., Dunlap S., Montpetit M., et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 80 8 (Oct 27 2005) 1019-1025